DAD study looking at safety of anti-HIV drugs to be extended and expanded
This article was originally published in Scrip
The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study will continue for at least another four years, until 2012, and will also be expanded to look at possible new risks. This ensures that the study will remain one of the most powerful pharmacovigilance tools to monitor the long-term safety of antiretroviral medicines, the EMEAsays.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.